AAV therapies by convection enhanced delivery (CED): What to expect from non-clinical safety studies

被引：0
|
作者：
Vats, Srishti [1 ]
Bouchard, Amelie [1 ]
Foret, Morgan [1 ]
Maghezzi, Said [1 ]
Galicia, Archival [1 ]
Bennamoune, Nehla [1 ]
Authier, Simon [1 ]
机构：
[1] Charles River Labs, Laval, PQ, Canada
来源：
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS | 2023年 / 123卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
SP028
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies
    Lemmens, Myriam
    Dorsheimer, Lena
    Zeller, Andreas
    Dietz-Baum, Yasmin
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2024, 896
  • [32] Interferences of the autonomic nervous system with drug induced QT prolongation: A point to consider in non-clinical safety studies
    Champeroux, Pascal
    Ouille, Aude
    Martel, Eric
    Fowler, John Sinclair Lawrence
    Jude, Sebastien
    Lala, Patricia
    Le Guennec, Jean-Yves
    Richard, Serge
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2010, 61 (03) : 251 - 263
  • [33] Comparing non-clinical safety studies to pharmacovigilance evaluation for assessment of safety: the case of anti- COVID-19 vaccines in France
    Gonin, C.
    Louin, G.
    Kayrouh, C.
    Crommelynck, S.
    Chollet-Martin, S.
    Salomon, V.
    Pallardy, M.
    TOXICOLOGY LETTERS, 2024, 399 : S285 - S285
  • [34] Identification of different modes of viral transport in the non-human primate brain after convection-enhanced delivery of AAV serotype vectors
    Passini, M. A.
    Bu, J.
    Dodge, J. C.
    Shihabuddin, L. S.
    Taksir, T., V
    Griffiths, D. A.
    Bringas, J.
    Hadaczek, P.
    Avramut, M.
    Cheng, S. H.
    Bankiewicz, K. S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 30 - 30
  • [35] Identification of Different Modes of Viral Transport in the Non-Human Primate Brain after Convection-Enhanced Delivery of AAV Serotype Vectors
    Passini, Marco A.
    Bu, Jie
    Dodge, James C.
    Shihabuddin, Lamya S.
    Taksir, Tatyana V.
    Griffiths, Denise A.
    Bringas, John
    Hadaczek, Piotr
    Avramut, Mihaela
    Cheng, Seng H.
    Bankiewicz, Krystof
    MOLECULAR THERAPY, 2006, 13 : S1 - S1
  • [36] Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies
    Andrade, E. L.
    Bento, A. F.
    Cavalli, J.
    Oliveira, S. K.
    Schwanke, R. C.
    Siqueira, J. M.
    Freitas, C. S.
    Marcon, R.
    Calixto, J. B.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (12) : e5646
  • [37] CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
    Wallis, Rob
    Benson, Charles
    Darpo, Borje
    Gintant, Gary
    Kanda, Yasunari
    Prasad, Krishna
    Strauss, David G.
    Valentin, Jean-Pierre
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2018, 93 : 15 - 25
  • [38] GLP-Compliant Non-Clinical Safety and Biodistribution of a Recombinant AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI
    Ferla, Rita
    Marteau, Jean-Brice
    Pouillot, Severine
    Kozarsky, Karen
    Brown, James
    Galimberti, Stefania
    Valsecchi, Maria Grazia
    Zuliani, Vincent
    Auricchio, Alberto
    MOLECULAR THERAPY, 2016, 24 : S185 - S185
  • [39] EMS in Viracept-The course of events in 2007 and 2008 from the non-clinical safety point of view
    Mueller, Lutz
    Singer, Thomas
    TOXICOLOGY LETTERS, 2009, 190 (03) : 243 - 247
  • [40] GLP-compliant non-clinical safety and biodistribution of a recombinant AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI
    Ferla, R.
    Marteau, J. B.
    Alliegro, M.
    Pouillot, S.
    Kozarsky, K.
    Brown, J.
    Galimberti, S.
    Valsecchi, M. G.
    Zuliani, V.
    Auricchio, A.
    HUMAN GENE THERAPY, 2016, 27 (11) : A148 - A149
12345